Soleus Capital Management’s Indivior Pharmaceuticals INDV Stock Holding History

Soleus Capital Management’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$43.7M	Sell	1,064,000 -210,000	-16%	-$7.62M	1.5%	18
2026 Q1	$38.8M	Buy	1,274,000 +1,174,000	+1,174%	+$38.8M	1.57%	18
2025 Q4	$3.59M	Sell	100,000 -1,366,000	-93%	-$41.7M	0.13%	72
2025 Q3	$35.3M	Buy	+1,466,000	New	+$30.7M	1.78%	18
2023 Q3	–	Sell	-18,624	Closed	-$443K	–	104
2023 Q2	$443K	Buy	+18,624	New	+$427K	0.05%	98

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Soleus Capital Management's INDV Position: Q2 2026 in Review

Soleus Capital Management reduced its Indivior Pharmaceuticals (INDV) stake by 16% in Q2 2026, selling an estimated $7.62M and leaving 1,064,000 shares worth $43.7M. The position accounts for 1.5% of the portfolio, ranked #18.

Soleus Capital Management first reported a position in INDV in Q2 2023 and has held it in 5 quarters since. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

Soleus Capital Management held 1,064,000 shares of Indivior Pharmaceuticals worth $43.7M as of Q2 2026.
Soleus Capital Management sold 210,000 Indivior Pharmaceuticals shares in Q2 2026, an estimated $7.62M.
Indivior Pharmaceuticals made up 1.5% of Soleus Capital Management's portfolio in Q2 2026, its #18 holding.
Soleus Capital Management first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 5 quarters since.
338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.